Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma

Ricciardolo, Fabio Luigi Massimo; Blasi, Francesco; Centanni, Stefano; Rogliani, Paola

doi:10.1016/j.pupt.2015.05.006

Cited by 15 publications

(13 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inhibition of the proliferation of ASMCs was decisive for the treatment of asthma . A recent study recommended inhaled corticosteroids (ICS) as the most effective anti‐inflammatory treatment of persistent asthma . However, long‐term use of ICS therapy, especially in high dose, is potentially causing systemic adverse effects in children such as cataracts, impaired growth, skin thinning and bruising, as well as decreased bone mineral density .…”

Section: Introductionmentioning

confidence: 99%

Silencing of ADAM33 restrains proliferation and induces apoptosis of airway smooth muscle cells in ovalbumin‐induced asthma model

Zhou

Bai

Liu

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

A defibrinogen and metalloproteinase 33 (ADAM33) was reported to play an important role in asthma. Furthermore, ADAM33 may play a possible role in airway remodeling due to its high expression in myo‐/fibroblasts, epithelium, as well as the airway smooth muscle cells (ASMCs). Thus, the study is supposed to investigate the effect of the downregulation of ADAM33 on the proliferation and apoptosis of ASMCs in allergic asthma. An ovalbumin‐induced asthma model in rats was established for investigating the function of the silencing of ADAM33. ASMCs were cultured and divided into four groups after transfection. The messenger RNA and protein expressions of ADAM33 were measured by reverse transcription quantitative polymerase chain reaction and Western blot analysis. Cell proliferation was tested by cell counting kit‐8 and cell apoptosis by TdT‐mediated dUTP nick‐end labeling. The allergic asthma rats showed a large number of inflammatory cell infiltration, airway smooth muscle hypertrophy and hyperplasia, and increased WA t, WA m, and numbers of bronchial smooth muscle nucleus. Additionally, increased numbers of eosinophils and neutrophils, expressions of immunoglobulin E and interleukin‐4, content of airway air pressure, and NO, although decreased in expression of interferon‐γ, were exhibited in rats with allergic asthma. In our study, upregulated ADAM33 was found, and after the silencing of ADAM33, decreased proliferation and increased apoptosis of ASMCs were observed. The study evidences that silencing of ADAM33 can decrease the proliferation and increase the apoptosis of ASMCs in a rat model of allergic asthma, suggesting ADAM33 represents a potential investigative focus target aiding allergic asthma.

show abstract

Section: Introductionmentioning

confidence: 99%

Silencing of ADAM33 restrains proliferation and induces apoptosis of airway smooth muscle cells in ovalbumin‐induced asthma model

Zhou

Bai

Liu

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…12 h) bronchodilation (Johnson et al, ). Salmeterol offers effective protection against histamine‐induced bronchoconstriction, by decreasing airway resistance and improving the ventilation of patients (Mahler et al, ; Ricciardolo, Blasi, Centanni, & Rogliani, ). However, similarly to other β 2 ‐adrenoceptor agonists, the use of inhaled salmeterol has been associated with dose‐related cardiovascular and systemic effects such as increased heart rate, palpitations, tremor and changes in plasma glucose and potassium levels (Guhan et al, ).…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers

Soulele

Macheras

Karalis

2017

Biopharm & Drug Disp

View full text Add to dashboard Cite

Salmeterol (SAL) is a long-acting β2-adrenergic agonist, which is widely used in the therapy of asthma. The aim of this study was to investigate the pharmacokinetics (PK) of inhaled salmeterol in asthma patients using two different dry powder inhalers. This analysis was based on data from 45 subjects who participated in a two-sequence, four-period crossover bioequivalence (BE) study after single administration of the test (T) and reference (R) products. In order to mimic more closely the real treatment conditions, activated charcoal was not co-administered. Plasma concentration-time (C-t) data were initially analysed using classic non-compartmental PK approaches, while the main objective of the study was to apply population PK modeling. The relative fraction of the dose absorbed via the lungs (R ) was set as a parameter in the structural model. The plasma C-t profiles of salmeterol showed a biphasic time course indicating a parallel pulmonary and gastrointestinal (GI) absorption. A two-compartment disposition model with first order absorption from the GI and very rapid absorption from lungs (like an i.v. bolus) was found to describe successfully the C-t profiles of salmeterol. The estimated R value was 13% suggesting a high gut deposition of inhaled salmeterol. Women were found to exert less capability to eliminate salmeterol than men, while body weight (in allometric form) was found to be an important covariate on the peripheral volume of distribution.

show abstract

“…The inhalative application of glucocorticoids is one of the most effective anti‐inflammatory therapies for asthma bronchiale . Asthma represents a condition with a higher prevalence among elite athletes than the general population and, noteworthy, selected asthmatic athletes were shown to exhibit a low responsiveness to inhaled corticoids for yet unclear reasons .…”

Section: Glucocorticoidsmentioning

confidence: 99%

“…The inhalative application of glucocorticoids is one of the most effective anti-inflammatory therapies for asthma bronchiale. [218] Asthma represents a condition with a higher prevalence among elite athletes than the general population and, noteworthy, selected asthmatic athletes were shown to exhibit a low responsiveness to inhaled corticoids for yet unclear reasons. [219] Inhaled corticoids, designed in receptor binding affinity, selectivity, and dosage to ensure local rather than systemic exposure and activity [220] are permitted in sports in contrast to other routes of administration including oral, intravenous, intramuscular, and rectal applications.…”

Section: Glucocorticoidsmentioning

confidence: 99%

Annual banned‐substance review: analytical approaches in human sports drug testing

Thevis

Kuuranne

Walpurgis

et al. 2016

Drug Testing and Analysis

View full text Add to dashboard Cite

The aim of improving anti-doping efforts is predicated on several different pillars, including, amongst others, optimized analytical methods. These commonly result from exploiting most recent developments in analytical instrumentation as well as research data on elite athletes' physiology in general, and pharmacology, metabolism, elimination, and downstream effects of prohibited substances and methods of doping, in particular. The need for frequent and adequate adaptations of sports drug testing procedures has been incessant, largely due to the uninterrupted emergence of new chemical entities but also due to the apparent use of established or even obsolete drugs for reasons other than therapeutic means, such as assumed beneficial effects on endurance, strength, and regeneration capacities. Continuing the series of annual banned-substance reviews, literature concerning human sports drug testing published between October 2014 and September 2015 is summarized and reviewed in reference to the content of the 2015 Prohibited List as issued by the World Anti-Doping Agency (WADA), with particular emphasis on analytical approaches and their contribution to enhanced doping controls.

show abstract

Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma

Cited by 15 publications

References 118 publications

Silencing of ADAM33 restrains proliferation and induces apoptosis of airway smooth muscle cells in ovalbumin‐induced asthma model

Silencing of ADAM33 restrains proliferation and induces apoptosis of airway smooth muscle cells in ovalbumin‐induced asthma model

Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers

Annual banned‐substance review: analytical approaches in human sports drug testing

Contact Info

Product

Resources

About